Wall Street brokerages expect Emergent Biosolutions Inc (NYSE:EBS) to post $182.16 million in sales for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Emergent Biosolutions’ earnings. The highest sales estimate is $184.60 million and the lowest is $179.71 million. Emergent Biosolutions posted sales of $151.66 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 20.1%. The business is scheduled to issue its next quarterly earnings report on Thursday, February 22nd.

On average, analysts expect that Emergent Biosolutions will report full-year sales of $182.16 million for the current year, with estimates ranging from $546.78 million to $551.70 million. For the next year, analysts expect that the business will report sales of $683.58 million per share, with estimates ranging from $612.80 million to $742.90 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that follow Emergent Biosolutions.

Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported $0.73 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.41 by $0.32. Emergent Biosolutions had a net margin of 15.60% and a return on equity of 15.20%. The business had revenue of $149.43 million for the quarter, compared to analyst estimates of $124.55 million. During the same period in the prior year, the business posted $0.56 earnings per share. Emergent Biosolutions’s revenue was up 4.6% compared to the same quarter last year.

Several brokerages have commented on EBS. Zacks Investment Research raised shares of Emergent Biosolutions from a “hold” rating to a “strong-buy” rating and set a $53.00 target price for the company in a research note on Tuesday. Wells Fargo & Co reaffirmed an “outperform” rating and issued a $43.00 target price (up previously from $41.00) on shares of Emergent Biosolutions in a research note on Saturday, September 30th. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $47.67.

In other Emergent Biosolutions news, Chairman Fuad El-Hibri sold 40,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 14th. The shares were sold at an average price of $40.37, for a total value of $1,614,800.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Daniel Abdun-Nabi sold 31,508 shares of the company’s stock in a transaction that occurred on Friday, November 3rd. The shares were sold at an average price of $42.77, for a total transaction of $1,347,597.16. Following the completion of the sale, the chief executive officer now directly owns 215,642 shares of the company’s stock, valued at approximately $9,223,008.34. The disclosure for this sale can be found here. Insiders sold 206,329 shares of company stock valued at $8,892,362 in the last ninety days. Insiders own 16.50% of the company’s stock.

Large investors have recently modified their holdings of the business. Insight Capital Research & Management Inc. bought a new stake in shares of Emergent Biosolutions during the third quarter worth $1,272,000. California Public Employees Retirement System increased its position in shares of Emergent Biosolutions by 5.6% during the third quarter. California Public Employees Retirement System now owns 52,276 shares of the biopharmaceutical company’s stock worth $2,115,000 after acquiring an additional 2,776 shares in the last quarter. Cubist Systematic Strategies LLC bought a new stake in shares of Emergent Biosolutions during the third quarter worth $234,000. Cornerstone Capital Management Holdings LLC. increased its position in shares of Emergent Biosolutions by 11.9% during the third quarter. Cornerstone Capital Management Holdings LLC. now owns 20,680 shares of the biopharmaceutical company’s stock worth $835,000 after acquiring an additional 2,200 shares in the last quarter. Finally, First Republic Investment Management Inc. increased its position in shares of Emergent Biosolutions by 17.1% during the third quarter. First Republic Investment Management Inc. now owns 8,863 shares of the biopharmaceutical company’s stock worth $359,000 after acquiring an additional 1,296 shares in the last quarter. 88.44% of the stock is owned by hedge funds and other institutional investors.

Shares of Emergent Biosolutions (NYSE EBS) traded up $1.30 during trading hours on Wednesday, reaching $49.08. 318,241 shares of the company’s stock traded hands, compared to its average volume of 309,858. Emergent Biosolutions has a 1 year low of $27.94 and a 1 year high of $49.25. The company has a debt-to-equity ratio of 0.38, a current ratio of 7.37 and a quick ratio of 6.46. The company has a market capitalization of $1,977.87, a P/E ratio of 29.04, a PEG ratio of 0.92 and a beta of 1.25.

ILLEGAL ACTIVITY NOTICE: This story was originally published by Marea Informative and is the sole property of of Marea Informative. If you are reading this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The legal version of this story can be viewed at https://www.mareainformativa.com/emergent-biosolutions-inc-ebs-expected-to-post-quarterly-sales-of-182-16-million-updated-updated-updated/124379/.

About Emergent Biosolutions

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

Get a free copy of the Zacks research report on Emergent Biosolutions (EBS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.